174 related articles for article (PubMed ID: 3257274)
1. Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.
Belldegrun A; Uppenkamp I; Rosenberg SA
J Urol; 1988 Jan; 139(1):150-5. PubMed ID: 3257274
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
3. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
5. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
[TBL] [Abstract][Full Text] [Related]
8. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
[TBL] [Abstract][Full Text] [Related]
9. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.
Brandau S; Suttmann H; Flad HD; Jocham D; Böhle A
Cancer Immunol Immunother; 2000 Sep; 49(7):369-76. PubMed ID: 10999463
[TBL] [Abstract][Full Text] [Related]
10. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
11. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
12. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
[TBL] [Abstract][Full Text] [Related]
13. Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay.
Kanamaru H; Yoshida O
Urol Res; 1989; 17(4):259-64. PubMed ID: 2788951
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
15. Different susceptibilities of lymphokine-activated killer cells (LAK cells) among primary and metastatic renal cell carcinoma derived from the same patient.
Hattori T; Satoh M; Nishimura T; Kawamura N; Akimoto M
Br J Urol; 1995 Apr; 75(4):448-51. PubMed ID: 7788254
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
17. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
18. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
19. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]